Catalyst Wire Dossier Catalyst Wire Dossier

Exelon Patch (rivastigmine transdermal patch) 10 cm²

rivastigmine transdermal patch · Novartis Pharmaceuticals
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Exelon Patch (rivastigmine transdermal patch) 10 cm², covering 2017-03-28 to 2017-03-28. Get the full timeline:

Most recent: Clinical Trial Update: Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease. [Phase 4]

See pricing